rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


12345678910111213...1617»
  • ||||||||||  Aduhelm (aducanumab) / Neurimmune, Eisai, Leqembi (lecanemab-irmb) / Biogen, Eisai, Kisunla (donanemab-azbt) / Eli Lilly
    Journal:  Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective. (Pubmed Central) -  Sep 20, 2024   
    Another medication that can temporarily alleviate dementia symptoms is memantine, which blocks the N-methyl-D-aspartate (NMDA) receptor...For some Alzheimer's pa-tients, the FDA-approved monoclonal antibody, aducanumab, is an option; for others, phase 3 clinical studies are underway for drugs, like lecanemab and donanemab, which have demonstrat-ed potential in eliminating amyloid protein. However, additional study is required to identify and address these limitations in order to reduce the likelihood of side effects and maximize the thera-peutic efficacy.
  • ||||||||||  Kisunla (donanemab-azbt) / Eli Lilly
    Journal:  Donanemab (Kisunla) for Alzheimer's disease. (Pubmed Central) -  Aug 13, 2024   
    In the present article, we evaluate the therapeutic potential of different PDE5 inhibitors to outline their multifaceted impact in the NCDs. No abstract available
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal, Immune cell:  Effect of acetylcholinesterase inhibition on immune cells in the murine intestinal mucosa. (Pubmed Central) -  Jul 29, 2024   
    The present study aims to investigate the effect that rivastigmine, a reversible AChE inhibitor used for the treatment of neurodegenerative diseases, has on the murine immune defenses of the intestinal mucosa...Our findings indicate the requirement for persistent cholinergic pathway engagement to effect a change in the cellular landscape of the mucosal tissue that is necessary for protection against lethal bacterial infections. Moreover, optimal protection requires a collaboration between innate and adaptive mucosal immune responses in the intestine.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  New biologically active sulfonamides as potential drugs for Alzheimer's disease. (Pubmed Central) -  Jun 28, 2024   
    Regression analysis of the obtained dissolution profiles was performed, and the effects of the pH and the release mechanism were determined. Some substances showed remarkable biological activity and became a subject of interest for further extensive study.
  • ||||||||||  Cognex (tacrine) / Shionogi
    Review, Journal:  Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders. (Pubmed Central) -  Jun 27, 2024   
    This necessity has led to the incorporation advanced technologies like artificial intelligence and machine learning into the drug discovery process for neurodegenerative diseases. These technologies help identify therapeutic targets and optimize lead compounds, offering a more effective approach to addressing the challenges of AD and similar conditions.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  In silico analysis of the use of solanine derivatives as a treatment for Alzheimer's disease. (Pubmed Central) -  Jun 24, 2024   
    PyRx default sorter was used to improve docking accuracy. Four compounds were selected based on their higher binding affinities in chain A and B. The results showed that Solanine derivatives (alpha-Solanine, Beta1-Solanine and Beta2-Solanine) have higher binding strength (-9.0,-9.3 and -8.6) than Rivastigmine (-7.2) in chain A, and also the binding strength was high for the Solanine derivatives (alpha-Solanine, Beta1-Solanine, and Beta2-Solanine) (-9.0,-8.8 and -8.9) is higher than Rivastigmine (-6.0) in the chain B. Solanine derivatives showed higher binding strength with acetylcholinesterase, potentially for to reduce the progression of the disease.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment (Exhibit (Pennsylvania Convention Center); In-Person) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_3130;    
    Four compounds were selected based on their higher binding affinities in chain A and B. The results showed that Solanine derivatives (alpha-Solanine, Beta1-Solanine and Beta2-Solanine) have higher binding strength (-9.0,-9.3 and -8.6) than Rivastigmine (-7.2) in chain A, and also the binding strength was high for the Solanine derivatives (alpha-Solanine, Beta1-Solanine, and Beta2-Solanine) (-9.0,-8.8 and -8.9) is higher than Rivastigmine (-6.0) in the chain B. Solanine derivatives showed higher binding strength with acetylcholinesterase, potentially for to reduce the progression of the disease. We analyzed electronic health record and claims data for patients diagnosed with AD, DLB, or VD between October 2015 and August 2022 from a large healthcare system in the U.S. Claims for ChEI prescriptions (donepezil, galantamine, rivastigmine) were identified in the
  • ||||||||||  hyoscine butylbromide oral / Generic mfg., rivastigmine / Generic mfg.
    Synthesis and biological evaluation of some novel coumarin-oxadiazole conjugates as potential candidates for the treatment of cognitive decline (Exhibit (Pennsylvania Convention Center); In-Person) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_2522;    
    After i n vitro studies, the compounds have been evaluated against behavioural alterations using step down passive avoidance and escape learning protocol at a dose of 2.0 mg/kg with reference to standard drug, rivastigmine. Our results depicted that the anti-amnesic effect of the synthesized conjugates on scopolamine-induced memory impairment may be related to the mediation of the cholinergic nervous system and their effective antioxidant activity.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Therapeutic potential of beta-carotene on intracisternal injection of glucose oxidase-induced senile dementia in diabetic rats (Virtual) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_2265;    
    Besides, only a few medications were approved for the symptomatic relief of SD i.e., donepezil, galantamine, rivastigmine, and memantine. The present results revealed that BC possesses the ameliorative potential against GOD-induced neurotoxicity and SD due to its anti-oxidative, anti-cholinesterase, reduction of IR, prevention of microglial activation, and enhancement of the glucose update actions.
  • ||||||||||  Aduhelm (aducanumab) / Neurimmune, Eisai, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, donanemab (LY3002813) / Eli Lilly
    Review, Journal:  Alzheimer's disease and its treatment-yesterday, today, and tomorrow. (Pubmed Central) -  Jun 13, 2024   
    monoclonal antibodies (MABs), namely, aducanumab, lecanemab and donanemab...A comparison of the benefits and disadvantages of the different classes of drugs forms the basis for determining new directions for research and alternative drug targets that are undergoing pre-clinical and clinical assessments. In addition, we discuss and stress the importance of the treatment of the co-morbidities, including hypertension, diabetes, obesity and depression that are known to increase the risk of developing AD.
  • ||||||||||  Adlarity (donepezil transdermal system) / Corium
    Review, Journal:  The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review. (Pubmed Central) -  May 24, 2024   
    Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers...The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments...In addition, there is no high dose (e.g. 23?mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.
  • ||||||||||  rivastigmine / Generic mfg.
    Trial completion date, Trial primary completion date:  Toward a Computationally-Informed, Personalized Treatment for Hallucinations (clinicaltrials.gov) -  May 20, 2024   
    P1,  N=35, Recruiting, 
    Further consensus in the pharmacological management of patients living with dementia is urgently needed. Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Treatment of Anticholinergic Delirium with Oral Rivastigmine: A Case Report. (Pubmed Central) -  May 19, 2024   
    Oral rivastigmine has been applied successfully here and in other case reports to reverse anticholinergic delirium with the benefit of prolonged agitation control. Emergency physicians may consider this medication in consultation with a specialist, with initial doses starting at 4.5-6 mg, if encountering anticholinergic delirium when physostigmine is not available.
  • ||||||||||  galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Alkaloids as drug leads in Alzheimer's treatment: Mechanistic and therapeutic insights. (Pubmed Central) -  May 9, 2024   
    A pharmaceutical option containing an alkaloid may potentially slow down the progression of AD while enhancing its symptoms. This review highlights the potential of alkaloids as valuable drug leads in treating AD, providing a comprehensive understanding of their mechanisms of action and therapeutic implications.
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. (Pubmed Central) -  Apr 16, 2024   
    This phenotype is reversible by HMTM, but at the same time appears to be subject to a homeostatic regulation induced by chronic pre-treatment with an acetylcholinesterase inhibitor, which interferes with the efficacy of HMTM. The strongest phenotypic reversal coincided with a normalization of the tau load in the cortex and hippocampus of L1, suggesting that tau accumulation underpins the loss of cholinergic markers in the basal forebrain and its projection targets.
  • ||||||||||  donepezil / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease. (Pubmed Central) -  Mar 26, 2024   
    Further, various subtypes of muscarinic and nicotinic receptors involved in the cognition and pathophysiology of AD are described in detail. The article also reviewed primary neurotransmitters that regulate cognitive processes by modulating basal forebrain cholinergic projection neurons.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Rivastigmine for the management of anticholinergic delirium. (Pubmed Central) -  Mar 22, 2024   
    Rivastigmine can be used to treat anticholinergic delirium. In our case series oral rivastigmine appeared more effective than transdermal rivastigmine.